Camlin Fine Sciences Ltd
NSE:CAMLINFINE
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
American Express Co
NYSE:AXP
|
Financial Services
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Target Corp
NYSE:TGT
|
Retail
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
| US |
|
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
| US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
86.95
137.8
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Estee Lauder Companies Inc
NYSE:EL
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Church & Dwight Co Inc
NYSE:CHD
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
American Express Co
NYSE:AXP
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Target Corp
NYSE:TGT
|
US |
|
|
Walt Disney Co
NYSE:DIS
|
US |
|
|
Mueller Industries Inc
NYSE:MLI
|
US |
|
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Camlin Fine Sciences Ltd
You don't have any saved screeners yet
Good day, ladies and gentlemen, and welcome to the Q1 FY '23 Earnings Conference Call of Camlin Fine Sciences Limited., hosted by Sunidhi Securities & Finance Limited. [Operator Instructions] Please note that this conference is being recorded.
I now hand the conference over to Mr. Ashish Dandekar, Chairman and Managing Director. Thank you, and over to you, sir.
Thank you. Ladies and gentlemen, welcome to the quarterly earnings concall of our company.
As we have always done, our CFO, Mr. Santosh Parab, will first give you a brief of the quarter's performance and details, after which we will be answering your questions with Mr. [ Abhishek ] Nirmal Momaya, our Executive Director and Managing Director.
So without further ado, over to you, Santosh.
Thanks, Ashish. Once again, welcome, and thank you for joining us for the earnings call for our financial results for the quarter ended 30th of June '23. We appreciate your presence, especially at the cusp of a long weekend.
Just as a reminder, today's discussion may include certain forward-looking statements, which must be viewed in conjunction with the various risks involved in our businesses. As usual for ease of understanding at our outlook at consolidated financial results, despite the challenges in global markets [indiscernible] from the inflationary trends which further aggravated by significant volatility in the currency across the world.
CFS has been able to start the fiscal with an encouraging note, which can be seen from the result. This performance in the quarter is more than happening, especially in the backdrop of shut down for maintenance and upgradation of more than 4 weeks of our diphenol plant at Dahej. The consolidated revenue remains quite stable at INR 384 crores as compared to quarter 4, where it was at INR 389 crores. The operating EBITDA for the quarter has improved to 13% and stood at INR 48 crores, as against INR 6 crores and INR 24 crores in the last quarter.
The exemplary increase in power cost in Europe due to Russia-Ukraine crisis, it started last quarter remained at the similar levels. But the favorable currency movement and increase in selling prices did help us to recoup some of these higher costs.
Apart from the impact on the diphenol production due to shut down and upgradation during this quarter, all other product lines are fired on all cylinders. Since 1H is where standalone operations was negated by action losses in the subsidiaries, the other income on consolidated level stood at -- around INR 1 crore. Consolidated profit before tax stood at around INR 15 crores as compared to last quarter of INR 20 crores. The tax movement was high, [ as the ] in turn sovereign [ set up ] of tax losses are not large.
In the last quarter, if you remember, we had informed you that the debottlenecking and upgradation of diphenol plant was completed in mid-May '22, whereby the capacity was enhanced to 15,000 metric tonne per annum from the existing 10,000 metric tonne per annum.
We expect to gradually ramp this up to have the production grow now optimal capacity in the next 2 quarters. We are looking at this year for sustainable growth, based on emphasis on integration and innovation. As you know, we are forward integrating our diphenol catechol line by manufacturing and [indiscernible].
As a part of that effort, we are confident that commercializing volume in production and this newly constructed plant in Dahej very soon. With aroma of products back and with enhanced capacity of diphenols, this augurs well to achieve a sustainable growth.
Coming down to brief on the business of the subsidiaries, U.S. -- CFS Europe recorded a [ turnover ] of INR 132 crores in the current quarter. CFS Europe, as you know, has incurred higher energy cost due to the increase in gas prices in Europe. It was able to recover some of these [ escalated ] energy costs due to the -- by increasing the selling prices in this quarter.
As I said earlier, there has been no respite on the increased energy costs, [ although ] there was some relief as the prices have increased at much lower pace than in earlier quarters of the gas prices.
CFS Mexico has again broke its record of highest turnover in this quarter by posting a total revenue of around INR 90 crores, the clocked turnover of INR 77 crores in last quarter. CFS Mexico is expected to continue its stellar performance.
CFS Brazil and CFS North America with turnover of INR 27 crores and INR 17 crores, respectively, in the current quarter, are expected to keep improving their performance in the subsequent quarter.
Our Chinese subsidiary, which used to manufacture [ vanillin ] remains closed awaiting the order from China Supreme Court. With that time line, yet cannot be determined, we are [indiscernible] the receipt of order this -- sometime in this financial year. The Chinese plant will remain [ closed till ] that.
Coming to the matter -- coming to our CRAM's project, which is with Lockheed Martin. The discussions with them are still in progress of supplying a proprietary chemical, for battery storage system. We are definitely looking at achieving commercial product supply to them in sometime [ 2022]. We'll be sharing more information on it in the coming quarters.
With this, I will request to open the floor to Mr. Nirmal Momaya, our MD, Ashish Dandekar and myself are here to answer the questions. Thank you.
[Operator Instructions] The first question is from the line of Surya Narayan Patra from PhillipCapital.
Congrats with a great set of numbers in the difficult time, sir. The first question is on the impact of a plant shutdown. So since we have not been importing any hydroquinone from European operations. So during this 1-month kind of a shutdown of the Dahej facility, whether the tariff would also got impacted? And could you please quantify what business that we would have lost in the stand-alone operation for the quarter?
So in the stand-alone, we did import some hydroquinone from Italy, which was consumed in this quarter. So it's not that there was no import, but it was a very limited quantity. We do see that we -- in terms of volumes for the downstream products, on a stand-alone basis, so there is an impact, of course On the upstream on hydroquinone and catechol, where the production was half of what it should have been on capacity.
And in the downstream products, I would say that they were impacted by about 20% or so in terms of volume. So in value because prices have gone up, it kind of got a bit of a catch-up. But yes, if you were to look at it overall, diphenol was at 50% and the other downstream were about 20% lower than previous quarter.
For the stand-alone business, that is how we should look at it?
Yes.
Okay. Okay. Sir, with regards to the European operation, so could you share what is the EBIT for this quarter and versus last quarter, what is the kind of change even Y-o-Y basis?
Yes. So in -- this quarter, the EBITDA was INR 17 crores, and last quarter was INR 7 crores.
For Europe, sir?
For Europe, yes.
Okay. So sequentially, although there is a INR 5 crore kind of a incremental energy costs that we have witnessed, still, there is a kind of increment of INR 10 crores?
No. Due to pass on the price increases on hydroquinone in the European market.
Okay. So is it fair to believe that the EBITDA swing also what we are witnessing for the consolidated operation? So it is reflecting that only. It means savings in the SG&A cost. So around INR 10 crore kind of SG&A cost saving that we are witnessing despite of a INR 5 crore kind of a incremental rise in the energy cost, it is just to -- that reflects that. Is that correct, sir?
No. It is partly. I mean -- one of the things that has improved the margin. It's not the only thing.
Then what is the saving that is -- that we are witnessing? Sir, sequentially the SG&A cost for the quarter, if you see from the INR 125 crores to INR 115 crores it has become, while there is an increase in the INR 5 crore of energy cost. So that means almost like INR 15 crores kind of saving is the...
Surya -- Sorry, Santosh Parab here. Just to correct you on that. The last year's cost, the incremental INR 4 crores is on the base of quarter 4 costs.
Yes.
So one thing is that we have incurred some part of that INR 27 crores and some part of this INR 4 crores.
Okay. I was comparing exactly the sequential basis. In the previous quarter, consolidated EBIT other expenditure was INR 124 crores. In this quarter, it is INR 115 crore. So kind of a INR 10 crore saving, despite a INR 5 crore -- INR 4 crore kind of incremental energy cost?
So yes. So once saying that apart from that, what has happened in India, the operations were lesser, right? So that is -- the operating cost includes power cost in India. Other operating costs includes labor charges in India. So the throughput in India is lesser.
Now our output at Dahej, [indiscernible] said we were less about 15% on the diphenol line and 20% on other products. So the output in India. So comparatively because of the lower volumes, our operating cost in India is lesser. And that's why there is a reduction in operating costs on an overall basis, even though INR 4 crores of power costs increased outside India.
Okay. So then I think this is a strong margin scenario that we are witnessing for this quarter, sir. So given that as we are saying our vanilla plant is on track for commissioning in this quarter fully.
So then from the base of this 13 -- year ago was 13% kind of margin scenario in this quarter, we generally see is believed to be a lean quarter and that impacted with the shutdown. So are you giving an indication of a very strong improvement in the margin profile with vanilla coming up in the second quarter?
Yes. I mean the margin profile should improve as compared to the last quarter -- compared to Q1. Also, the rest of the year, we don't know what the pricing situation and raw material prices as well as selling price situation will be.
So difficult to predict beyond Q2. Q3, Q4, looking strong, but I mean there's so much volatility going on everywhere that it's very difficult to give a clear-cut guidance.
Okay. Okay. Sure. Sir, if you can talk something more on the vanilla plant. When are you thinking that, okay, it is commissioning? And how staggered manner that your utilization be progressing pricing scenario, what's that -- means the way that you're trying to play out this opportunity?
Yes. So we are expecting the commercial production to start by end of this quarter. So which means from Q3 we will start producing -- initially, the production will be at about 40% to 50% of capacity, which will get ramped up in the next -- after starting up in the next 3 to 4 months based on the market.
The market scenario yet remains short. Value is short, prices are yet over $20. So in that sense, the pricing scenario seems to be holding.
Okay. And even the cost -- the elevated cost scenario, which is visible, possibly will be helping the prices to remain elevated only for vanilla, is that right, sir?
It seems to be. But of course, since demand-supply both also play a role. It's not only cost. So -- but I mean what indications you are getting is that it should in the short term, the -- it will be short.
Okay. Just last question. On the blends side, sir, it seems that there is a kind of a strong recovery in that, I'd say, a strong performance based of a profit sense, right, on the blends side. So whether what we have been anticipating ramp-up in the blends and which could not happen during the COVID during the last 3 quarters.
So are you seeing kind of a real ramp-up now starting from the first quarter itself? And this is a kind of a progressive run rate that we should see from here on?
Yes. So in the first -- in Q4 '22, it was about INR 110 crores. And in Q1, it's about 125. So yes, there has been an improvement in this quarter. And I think the trend is showing that there will be further improvement.
Sure. Any specific thing that is driving this, sir?
So I think it's just that customers have opened up there is the interactions, which were restricted during COVID. I think all of that is now kind of, in the last 3, 4 months, has meet up. So I think it's just the interaction and approaches are now much easier.
[Operator Instructions] The next question is from the line of Amit Shah from [ East Securities ].
Sir, I have a couple of questions. Sir, firstly, I would like to understand a bit more on our businesses in Brazil and Mexico. Which are the key products which we manufacture in Brazil and Mexico? And how is this region performing for us? What kind of opportunities are we seeing in Latin America?
Basically, we focus really on Shelf-Life Solutions. And the products that we make there are essentially for, I would say, 60% of the businesses for extending Shelf-Life of food, animal feed, biodiesel, pet food and some of the other nutritional products for the animal feed market, some bactericides, some mold inhibitors.
So it's a whole bacterial product that we have there. The market opportunity is significant. And our performance in Mexico had been very strong. Brazil is picking up, post-COVID. Now, we are again back to -- believe in customers and starting to make approaches in the market.
Okay. Sir, how is the competition over there?
Competition is very strong. Competition is very strong there.
Okay. Sir, and a follow-up question. Sir, how do we source our raw materials for Latin America facility? Are we facing any challenges in sourcing them?
Yes. I mean, there are challenges. But I think we've kind of mitigated the risk by making interventions to see to it that we don't get stocked out. So I mean, I would say, generally, we are okay on the sourcing.
[Operator Instructions] The next question is from the line of Nirali Gopani from Unique Asset Management.
Sir, on just seeing a significant improvement in our gross margin, it's a higher than we have seen in the last 5 quarters. So is it largely because of your passed on the fuel price hike through the pricing inventory, are you seeing this hike and to the short-term number that we are seeing?
Yes. We've been able to pass on the cost increases. Of course, there's a lag between the time we can pass on the price increases. Generally it's a quarter lag. And I think, in the last quarter, raw material prices were quite stable. So therefore, we did the catch-up and, the margins have come back to where they were.
Okay. So sir, normally, we -- the guidance on a gross margin of roughly about 47% to 50%. So is this number sustainable or we go back to 50%?
So the gross margin is 55%. We will go back to 50%.
We'll do that. Does seem to be -- I mean I think we should be able to sustain it at least for 1 quarter. The next quarter, again, will depend on what the raw material prices are like.
Okay. Okay. And sir now the vanillin plant it was supposed to comment in June, right? So is there a reason for the delay?
No, no real reason for the delay. We were -- the mechanical completion is done. Now we are doing the trial production, and we should be hopefully now coming to commercialization soon.
Okay. Okay. Can you just mention that currently, the vanillin price is about roughly $20? And in Q4, you mentioned it was roughly about $30 and even after we come in the prices estimate about $20. So any change in that view?
No, no change in the view. It's the same.
Okay. So do you see that even after we come into the market, the prices should sustain at about $20?
$20, that's what our expectation is at least for the initial phase.
Okay. Okay. And so the Dahej plant has been -- the shutdown is complete and everything also. Can you see a Q-on-Q improvement in our top line because vanillin is also coming are onstream from Q3? So what kind of top line can you see in this full year of FY '23?
So top line on the consolidated basis, yes, what we are projecting is around between INR 1,800 crores to INR 2,000 crores. So we continue to look at that kind of number.
Okay. And can we achieve an EBITDA margin of roughly about 15% on a consolidated basis for the full year?
Difficult to say. This margin, based on this raw material prices, the way they are fluctuating and also sales price realization, you don't know. But I mean it should improve from where we are because of our capacity enhancement and vanillin plant coming in, it should improve from where we are.
And Mr. Santosh, is set up on the tax [indiscernible], can you just elaborate a bit on that part?
So as we have been said in the past, also because of some subsidiaries and losses, we cannot set up the internal country losses -- a couple of subsidies with the subsidiaries because of the partnership volatility at certain losses. So those kinds of losses cannot be adjusted with the profits of the other country tax profit. So like Europe, Mexico and to some extent India has done taxable profit, but subsidiaries like Brazil and U.S. as well as landlords that we have some maintenance costs are making losses.
So the losses there cannot be set up with the profits of the other countries. So that's not it, actually taxes are higher. But as the year goes, we are looking at an overall tax rate after ingesting all the losses in the range of 30%, 31%.
For FY '23?
For FY '23.
[Operator Instructions] The next question is from the line of Aniket Inamdar, an individual investor.
My question is on the $20 price of [ ethylvanillin ] you mentioned. Considering that we are using our own low-cost materialize that in the presentation, wouldn't the gross margins for what have been produced during this year is much higher than our current gross margins overall?
It will be slightly higher, of course, because catechol. When we sell catechol, we sell it at a loss, and then we need that -- there will be an improvement in the gross margin for that piece of the business in the sense for that much amount of catechol that is consumed in managing for sure.
Okay. And basically considering this we're starting from the second half, we will be looking at what, 2,000 tonnes this year?
Yes. I mean, yes, that's right in that region. Yes.
[Operator Instructions] The next question is from the line of Anurag Patil from Roha Asset Managers.
Sir, in Europe, how are you seeing the demand environment currently?
So we sell -- from Europe into Europe, we sell hydroquinone, which is the demand is yet strong. From India, we do sell some products into Europe, which continue to remain on the same levels as they were last year.
Okay. But going in the next couple of quarters, do we say that sales from India to certain or there is a possibility that it can be impacted?
The European market?
Yes.
I think most of our business in the food and food chain, which doesn't really get very badly impacted. There are no big swings in that. So we don't expect -- in terms of volume, we don't expect to be impacted in the next few months.
Okay. And sir, from a medium-term perspective, 2, 3 years down the line, which of our segments like Shelf-Life to Performance Chemicals, which even do you see growing at a faster rate?
So aroma would be the fastest rate right now in the first couple of years because it's a brand-new facility and the capacity is 6,000 tonnes. So -- which will add in terms of percentage, it'll add the highest number.
And sir, for Shelf-Life and Performance Chemicals, what kind of a growth rate we can expect any ballpark area will be, sir?
Shelf-Life Solutions, ou blends business is growing at about 30% a year. Our TBHQ/BHA business will grow at about 15% to 20% a year. So -- about 25% a year.
And in Performance Chemicals, with the added capacity, I think in the next few years, we should be able to grow by about 20% a year on a volume basis. I'm talking everything on volume basis.
The next question is from the line of Harsh Jhanwar from Centrum PMS.
Sir, my question was regarding vanillin prices. So vanillin certainly have come up from $30 to $20. Sir, as I understand, currently, there is a demand-supply gap and supply is lesser than demand. So if you could help us understand why any reason for this price -- significant decline in prices, even though we are not commissioned our plant yet? And how do you see this pricing going ahead?
The pricing is even today in excess of $25. What we are saying is once we come into the market, we expect the price to come down to about $20.
The next question is from the line of Rohit Sinha from Sunidhi Securities.
Just one question on the [ capacity ] expansion at Dahej facility. So post this commissioning and surplus capacity of hydroquinone, just wanted to know how the further expansion or scope in the TBHQ, BHA and MEHQ segment and near-term outlook in the MEHQ segment?
So TBHQ, BHA, we are -- I think we've done some debottlenecking in those capacities, and we expect to push volumes on both those products in the next few quarters.
As far as MEHQ is concerned, we are in the process of finalizing our plan on what kind of volumes we want to -- what kind of volumes of hydroquinone do we want to divert to MEHQ. So that plan has yet been built.
Okay. I mean what kind of a overall market that is there for SME, CME in the MEHQ?
MEHQ overall market size is about 5,000 metric tonnes. So maybe 5,000 and 5,500. So yes, we have an opportunity to play in that market. But we've not yet decided as to how much of the hydroquinone will be used for MEHQ. Based on what we do for TBHQ/BHA, we will take a decision on how much will go into MEHQ.
And the pricing difference between TBHQ and MEHQ would be significant?
Yes, yes. Significant. TBHQ is much higher than MEHQ.
[Operator Instructions] The next question is from the line of Pankaj from Affluent Assets.
Am I audible?
Yes.
Well, sir, just wanted to understand, how -- you mentioned that the vanillin prices are currently trading at $25. And after your -- after commissioning of our plant, you expect it to come down to $20. So would our supply this so high that it will disrupt the whole volume -- demand-supply mismatch?
No, I mean you say just -- I mean an estimated, we don't know what profit it set, it may remain at 25, it maybe at 23. But I'm just saying that when our capacity is almost 20% of the global capacity. So once that's comes in, it will have some impact.
The $25 is because of vary the demand-supply at this point at present. So how much that would be corrected by our supply?
As I said, 20% of the capacity is what we are -- we will be producing. So there are no numbers available in the market to give you exactly what it is.
And are any other competitors of ours also coming up with the new capacity in this near future?
Not in our land.
In vanillin?
Yes.
In vanillin?
In vanillin. Yes.
No, no. in vanillin nothing in the pipeline, not that we've heard of anything.
Okay. Sir, second thing, you mentioned about our top line to be around 1,400 to 1,500 for this year. And...
1,800 to [ 2,000 ].
1,800 to 2,000. My mistake. So -- and how would be the margin scenario?
Sorry?
How do we expect the margin scenario?
Did we answer that question?
Sir, I think, I would have joined late little bit.
It's difficult to give a estimate of the margin because of the volatility in raw material prices, economic situations across the world. So it's difficult to give a margin projection.
Sir, at least, would it be better than what it was last year?
It should be, yes.
[Operator Instructions] The next question is from the line of Surya Narayan Patra from PhillipCapital.
Yes. And sir, can you just give some sense, since we have passed on the price or passed on the aggregated cost in the prices of hydroquinone in Europe. And we have seen the energy cost has really gone up 5x kind of a much significantly when compared to the previous quarter.
So current pricing would be how different from the price that you will be realizing here in India for hydroquinone?
Pricing basically across the world are generally more or less the same.
Okay. It is not a different relation for Europe and...
I mean, there will be a little bit of a difference. I would say about 10% or so.
Okay, okay. So if that is the case, then even the downstream also accordingly proportionately would have gone up for TBHQ/BHA, let's say?
Yes, of course. Yes.
Okay, okay. My second question is on, let's say, any progress on that heliotropin kind of [indiscernible], sir?
Yes. We made those applications in China. So we are waiting for the progress to happen there.
Okay. I mean so there is no investment as such as we would have started it, right?
No, no, no.
Okay, okay. And so given that this -- so I think we are kind of closing our heavy category with the vanilla plant. So hereon, is there any kind of a project in mind? Or what is the kind of CapEx plans that we can be thinking about, either it could be relating to AlgalR or whichever? So if you can give some sense on the CapEx?
We do not yet actually finalized anything. So right now we are yet saying that the maintenance CapEx that will be in INR 60 crores to INR 80 crores is what is envisaged.
Okay. For this year and the similar...
[indiscernible]
That is the kind of a number for the current year. And if not anything on the Lockheed Martin front, I think similar kind of trend that one should think even for next year?
Yes, that's right.
Okay. In fact, on the -- because of the elevated prices, did you face any kind of a rise in the working capital funding requirement sequentially? And whether any change in the debt level because of this pricing scenario and hence, more working capital conditions? Anything on that side, sir?
Today, we had shared at the last meeting also, since we are looking at sequential increase mainly recover the aroma business in the range of around INR 150 crores to INR 200 crores.
Looking at the costing and the shorter operating cycle, manufacturing margin in India, see we are looking at a range of around INR 30 crores to INR 40 crores, which will be required by the end of this year on our working capital.
And we achieved INR 200 crores-odd turnover or actually optimal capacity. So we will try to use our internal accruals of that. So push come to shove, there will be a INR 30 crores to INR 40 crores of working capital increase by the year.
And on an average basis, we have also been repaying loans of around INR 30 crores, INR 35 crores. And as you know, [indiscernible] of INR 100 crores is a convertible instrument. If they convert, I can reduce my loan portfolio of INR 100 crores overnight.
Okay. Okay. And one just last clarification. This minority interest gain, so what is that? And how to think about it?
Yes, good question. So as you know, if you see the group profile now, there are only 2 companies which have a minority interest. One is Mexico, but that minority say for the ministry around 1 per [indiscernible] 100%. And as for the contract, we don't have to share any profits from there that balance sheet.
Other bigger minority interest is a 49% what we have in China. In China, we have no revenue that we have to maintain the plant, most of legal costs, which are incur because as we know there's a -- is thing going on, and we are also post core different than in that case.
So these are this costs for maintaining minimal employees, maintaining the plant and some mill cost, costs some things cost. The share of that, naturally, see we share 50 or 49. So the [indiscernible] on that profit from the VAT is mainly on account to minority interest loss, which has been shared by the [ Chinee ] partner.
Okay. So that means til the time we are seeing any progress on the any drop in front at least, that is a kind of a cushion to our -- over a longer?
No, it is a future not [indiscernible] -- but yes, my operating profit, my PAT, my profit will be more than my PAT.
[Operator Instructions] Ladies and gentlemen, as there are no further questions, I would now like to hand the conference over to the management for closing comments.
Ladies and gentlemen, thank you very much for participating in this concall. We look forward to interacting with you again for the next one. Until then, have a good day. Thank you.
Thank you. On behalf of Sunidhi Securities & Finance Limited, that concludes this conference. Thank you for joining us, and you may now disconnect your lines.